Navigation Links
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
Date:4/29/2010

TROY, Mich., April 29 /PRNewswire/ -- Troy, Mich.-based law firm Frank, Haron, Weiner and Navarro, in conjunction with the United States Department of Justice, today announced a settlement in the amount of $75,370,000 for a lawsuit filed in 2003 against Raritan, N.J.-based pharmaceutical firm Ortho-McNeil-Janssen Pharmaceuticals, Inc. ("OMJPI"). The announcement was made by the Chair of the firm's False Claims Act practice David Haron and co-lead counsel Monica Navarro.

Filed in August, 2003 under the qui tam provisions of the federal False Claims Act (Title 31 United States Code, Section 3729) on behalf of Angela Maher and Anastasia (Stacey) Savka-Klovski, the lawsuit alleged that OMJPI acted improperly concerning the marketing, promotion and sale of the anticonvulsant drug Topamax®.  In December 2003, Dr. Gary R Spivack, represented by the Washington, D.C.-based law firm of Phillips & Cohen, filed a similar lawsuit.  The cases were consolidated and the settlement referenced here resolves both cases.

The settlement refers to government claims that OMJPI "illegally marketed Topamax® by, among other things, promoting the sale and use of Topamax® for a variety of psychiatric conditions other than those for which its use was approved by the Food and Drug Administration, (i.e. "off-label" uses)."  It also states that "certain of these uses were not medically-accepted indications for which State Medicaid programs provided coverage" and that as a result "OMJPI knowingly caused false or fraudulent claims for Topamax® to be submitted to, or caused purchase by, Medicaid, the TRICARE Program (formerly known as the Civilian Health and Medical Program of the Uniformed Services), the Federal Employees Health Benefits Program ("FEHBP"), and the Department of Veterans Affairs ("DVA")". OMJPI neither admitted nor denied liability, but OMJPI agreed to enter into a plea agreement with the government and has agreed to plead guilty to specific conduct described in the plea agreement to be filed in US v Ortho-McNeil Pharmaceutical, LLC, a criminal action in the District of Massachusetts.

Commenting on the settlement, Haron said, "We feel this is a fair settlement and thank Angela and Anastasia for identifying the fraudulent activity, bringing it to our attention and allowing us to work with them to stop it. My co-lead counsel, Monica Navarro, and our Associate, Maro Bush, would like to thank Colin M. Huntley, Trial Attorney, Commercial Litigation Branch, Civil Division, US Department of Justice and Zachary A. Cunha, Assistant US Attorney, US Attorney's Office, District of Massachusetts for bringing this nearly decade-long litigation to a successful conclusion."

"The government's annual healthcare expenses total nearly $1 trillion. It is estimated that nearly $100 billion of that money is lost each year to fraud, waste and abuse," continued Haron.  "Only when those aware of fraud bring it to the attention of lawyers who have the resources to investigate and verify the allegations can that money be retrieved. This case is an example of how the system is supposed to work and how it will work given the increased resources and enhanced anti-fraud provisions in the health reform legislation recently signed by President Obama."

The False Claims Act and similar state acts, such as the Michigan Medicaid False Claims Act, provides incentives to private citizens, called Relators, who discover fraud against the federal or state governments and who bring their information to the government and help pursue the defrauding entities. The qui tam provisions allow Relators to represent the interests of the government to seek damages and civil penalties for a violation of law and, if the action is successful, to receive a portion of the awarded damages.  

Under the terms of this agreement, the Relators will be awarded an 18% share of the recovery by the states. In addition, the Relators and the defendant have entered into a settlement regarding attorney's fees and costs.  

A boutique full service law firm located in Troy, Michigan, Frank, Haron, Weiner and Navarro specializes in complex litigation, whistleblower, federal, and state False Claims Act/Qui Tam litigation; as well as in health, business, employment, real estate; taxation, estate planning and probate law.


'/>"/>
SOURCE Frank, Haron, Weiner and Navarro
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
2. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... DALLAS , Feb. 10, 2016  Fotona, based in ... it will launch its new ST PRO Lightwalker dental laser ... Chicago Dental Society from 25-27 February, 2016 in booth #4815. ... tissue dental laser with many of the features of the ... $49,900, the ST PRO competitive price will be very attractive ...
(Date:2/10/2016)...   Genomic Health, Inc. (Nasdaq: GHDX ) today ... ended December 31, 2015. --> --> ... compared with $69.1 million in the fourth quarter of 2014, an ... 9 percent compared with the same period in the prior year. ... $63.9 million in the fourth quarter of 2015, an increase of ...
(Date:2/10/2016)...  Cepheid (Nasdaq: CPHD ) today announced ... President and Chief Operating Officer, has been promoted ... Officer.  In his new capacity, Mr. Kocmond,s responsibilities ... Operations in addition to Manufacturing Operations, Engineering, Technical ... to report to John Bishop , Cepheid,s ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... practitioner, is known locally for a series of therapeutic sessions to help Los ... their characters and in their lives. The series, known as “Mindfulness for Actors ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop ... revolutionary new 2.0 version at the International Roofing Expo in Orlando, Florida on ... the world's most advanced weather technology in the hands of consumers, roofing contractors, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency in Garland, ... the local community. Pledging to select a new beneficiary every 60 days, the ... Their goal is to bring community awareness to important local causes by forming ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
Breaking Medicine News(10 mins):